Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 6/20 | 0.47 |
| ▸ | GRM5 | P41594 | 5/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.33 |
| ▸ | HTR3A | P46098 | 2/20 | 0.32 |
| ▸ | F10 | P00742 | 2/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.31 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.31 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.31 |
| ▸ | HTR3B | O95264 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.31 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6411658 | 0.87 | CHRNA7 (0.39) | CHRNA7F10TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL6418521 | 0.87 | CHRNA7 (0.47) | CHRNA7 | |
| SCHEMBL6417960 | 0.86 | CHRNA7 (0.39) | CHRNA7GRM5TRPV1HTR3ATAS1R3 | |
| SCHEMBL6412411 | 0.84 | CHRNA7 (0.37) | CHRNA7 | |
| SCHEMBL6411983 | 0.84 | CHRNA7 (0.37) | CHRNA7GRM5 | |
| SCHEMBL6411706 | 0.84 | CHRNA7 (0.41) | CHRNA7GRM5TRPV1F10 | |
| SCHEMBL6411693 | 0.82 | TAS1R3 (0.34) | CHRNA7GRM5TRPV1F10TAS1R3 | |
| SCHEMBL6412091 | 0.81 | CHRNA7 (0.40) | CHRNA7GRM5TRPV1HTR3AF10 | |
| SCHEMBL6413960 | 0.81 | NPC1 (0.36) | CHRNA7GRM5TRPV1F10TAS1R3 | |
| SCHEMBL6411936 | 0.80 | NAMPT (0.41) | CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236264-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-20050215584-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PFIZER INC | 2005-09-29 | — | — | US | disclosed |
| US-6858613-B2 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PFIZER INC. (US) | 2005-02-22 | — | — | US | disclosed |
| US-20030236264-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236264-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | NAT1, CYP11B1, COASY | CHRNA7 1475/4885GRM5 680/4885TRPV1 2510/4885 |
| US-20050215584-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | CHRNA7, UGT2B7, CHRNA5 | CHRNA7 1/4885GRM5 74/4885TRPV1 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.